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Background: Surveillance of HIV-1 drug resistance in treated patients with plasma viral load (VL) .50 copies/
mL.
Methods: The protease and reverse transcriptase (RT) genes were systematically sequenced in samples from
756 patients with VL .50 copies/mL in 2009. The genotyping results were interpreted for each antiretroviral
drug (ARV) by using the ANRS algorithm v21. Weighted analyses were used to derive representative estimates
of percentages of patients. Prevalence rates were compared with those obtained in 2004 among patients with
VL .1000 copies/mL.
Results: Sequences were obtained for 506 patients. Sequencing was successful in 45%, 80% and 96% of
samples with VL of 51–500, 501–1000 and .1000 copies/mL, respectively. Resistance or possible resistance
to at least one ARV was observed in 59% of samples. Overall, 0.9% of samples contained viruses resistant
to all drugs belonging to at least three drug classes. All resistance prevalence rates were significantly lower
in 2009 than in 2004.
Conclusion: In France, where 86% of patients were receiving combination antiretroviral therapy in 2009, only
15.0% of patients had a VL .50 copies/mL, suggesting that only 8.9% of treated patients could potentially
transmit resistant viruses. Only 0.08% of patients harboured viruses fully resistant to at least three antiretroviral
drug classes. Further studies are needed to determine whether resistance continues to decline over time.
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Introduction
The use of combined antiretroviral therapy (cART) has led to a
marked fall in HIV/AIDS-related morbidity and mortality.1,2
However, viruses resistant to all classes of antiretroviral drugs can
be selected during treatment and can lead to virological failure.3
Resistant viruses may be acquired at the time of primary infection
or, more importantly, be selected during virological failure on cART.
It is important to monitor the prevalence of drug-resistant HIV in
treated patients, both to limit the spread of resistance and to deter-
mine the proportion of patients requiring new therapeutic options.
We therefore conducted a systematic nationwide survey of HIV-1
resistance in patients with virological failure in France, and com-
pared the results with those obtained in 2004.4
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Patients and methods
Study population
HIV-1-infected patients were included in this study if they had been re-
ceiving cART for at least 6 months and if they had a confirmed plasma
HIV-1 RNA value .50 copies/mL between April and September 2009.
Up to 30 consecutive patients were enrolled in each participating virology
laboratory. Participating laboratories belonged to the Agence Nationale
de Recherches sur le SIDA et les He´patites Virales (ANRS) AC11 network
and participated in the ANRS quality control assessment of HIV-1 drug re-
sistance sequencing.5 The study was approved by the Comite´ Consultatif
de Traitement de l’Information dans la Recherche Scientifique et Me´di-
cale (CCTIRS) and the Commission Nationale Informatique et Liberte´s
(CNIL), in keeping with French law. The patients received full information
concerning their participation in the study.
Genotypic resistance analysis
The sequences of the protease, reverse transcriptase (RT), gp41 and inte-
grase genes were determined in each laboratory, using the ANRS consen-
sus technique (http://www.hivfrenchresistance.org), the Bayer TrueGene kit
(Siemens Medical Solutions Diagnostics, Tarrytown, NY), the Abbott ViroSeq
kit (Abbott Laboratories, Abbott Park, IL) or an in-house method. The gp41
and integrase genes were only sequenced if the patient was receiving enfu-
virtide or raltegravir, respectively. Primary and secondary protease, RT, inte-
grase and gp41 gene mutations were identified from the International
AIDS Society resistance testing USA panel (http://www.iasusa.org/
resistance_mutations/mutations_figures.pdf; update November 2011).
Data collection
Sociodemographic data, clinical data, treatment histories and the treat-
ment regimen at the time of virological failure were routinely collected.
Respect for the inclusion criteria and all recorded data were checked by
study monitors.
The deduced amino acid sequences of the different genes were col-
lected in text or FASTA format and integrated in a specifically developed
Accessw database application.
Statistical analysis
Weighted analyses were used to derive representative estimates of the
percentages of patients harbouring viruses with mutations conferring re-
sistance to drugs belonging to the nucleoside reverse transcriptase inhibi-
tor (NRTI), protease inhibitor (PI) and non-NRTI (NNRTI) classes, weighting
being based on the number of patients followed in each centre. The esti-
mates of the number of patients followed in each centre were derived
from the French Hospital Database on HIV (FHDH ANRS CO4) and from
the ANRS Aquitaine CO3 Cohort. Crude analysis (without weighting)
was used to estimate the percentages of patients harbouring viruses
with mutations conferring resistance to an integrase or gp41 class
drug, as the integrase and gp41 genes were only sequenced in patients
receiving raltegravir or enfuvirtide. The data for enfuvirtide resistance
mutations are not shown, because of the small sample size (n¼4).
Results are expressed as medians and IQRs or percentages.
The genotyping results were interpreted for each drug by using the
ANRS algorithm (http://www.hivfrenchresistance.org; update October
2011, version 21). We also used the Stanford algorithm (http://hivdb.
stanford.edu; update November 2011) to interpret resistance to tiprana-
vir in patients with non-B viruses, as the ANRS algorithm for tipranavir is
only valid for subtype B. The ANRS algorithm designates viruses as resist-
ant (R), possibly resistant (I) or susceptible (S). In the Stanford system,
viruses are ranked as follows: susceptible, potential low-level resistance,
low-level resistance, intermediate resistance or high-level resistance. To
condense these categories into three levels of resistance, we grouped
the first two levels in category S, the third and fourth in category I,
and the fifth in category R. We considered that an isolate was completely
resistant to a class of drugs when it was ranked as resistant or possibly
resistant to all the drugs considered for the class.
The rates of successful sequencing and of resistance to each drug and
each class of drugs were analysed according to the plasma HIV-RNA level
(51–500, 501–1000 and .1000 copies/mL). The x2 test or Fisher’s exact
test was used to compare categorical variables and the Mann–Whitney
U-test was used to compare continuous variables. Multivariable logistic
models were used to identify factors associated with the risk of RT or pro-
tease gene amplification failure. Variables with univariate P values ,0.15
were included in multivariable logistic models.
We used FHDH ANRS CO4 to estimate the percentage of HIV-
1-infected patients receiving cART in 2009 and the percentage of those
with viral load .50 copies/mL. This allowed us to estimate the percent-
age of treated patients who could potentially transmit resistant viruses
and the percentage of treated patients harbouring viruses with complete
resistance to at least three classes of drugs.
Amino acid sequences (n¼498) obtained during our previous survey
(Multivir 2004)4 were re-analysed with the algorithms used in the
present survey (Multivir 2009) in order to compare the frequencies of
drug resistance between the two surveys in patients with plasma
HIV-RNA.1000 copies/mL, as this was an inclusion criterion in the Multi-
vir 2004 study.
The SPSS software package version 19.0 for Windows (SPSS Inc.,
Chicago, IL, USA) and SASw statistical software version 9.3 (SAS Institute,
Inc., Cary, NC, USA) were used for all analyses.
Results
Characteristics of the patients
Nine hundred treated HIV-1-infected patients with viral load
.50 copies/mL were screened between April and September
2009 in 33 French laboratories and 1 Swiss laboratory for inclu-
sion in this study. One hundred and forty-four patients were
ineligible [inclusion criteria not met (n¼62) or viral load
,50 copies/mL at the last visit (n¼82)]. The protease and RT
genes were successfully sequenced in 506 of the remaining
756 patients. Amplification was attempted in 60 of the 97
patients receiving raltegravir and was successful in 35 cases.
Two-thirds of the patients were men, and the median age
was 46 years (IQR 39–51 years). Median plasma viral load
was 2.57 log10 copies/mL (IQR 2.05–3.49). The percentage of
patients with plasma viral load .1000 copies/mL was 35.6.
The median CD4 cell count was 390 cells/mm3 (IQR 225–581).
The patients had been exposed to a median of 8 antiretroviral
drugs overall (IQR 6–10) and to 5 NRTIs (IQR 3–6), 2 PIs (IQR
1–3) and 1 NNRTI (IQR 0–1). The median total duration of ART
was 10.4 years (IQR 4.6–13.4). Fifty-eight percent of patients had
received three different drug classes. The antiretroviral treatments
at the time of virological failure were tenofovir (58.6%), emtricitabine
(48.4%), lamivudine (34.9%), abacavir (29.7%), zidovudine (12.1%),
didanosine (5.9%), stavudine (1.4%), efavirenz (9.1%), etravirine
(6.5%), nevirapine (5.5%), lopinavir/ritonavir (27.4%), atazanavir
(26.5%) including atazanavir/ritonavir (21.9%), darunavir/ritonavir
(14.7%), saquinavir/ritonavir (3.9%), fosamprenavir/ritonavir (2.8%),
tipranavir/ritonavir (2.1%), indinavir (0.6%) including indinavir/ritonavir
(0.3%), raltegravir (13.3%), maraviroc (2.2%) and enfuvirtide
(1.5%).
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Factors predictive of amplification failure
Exposure to the different drugs at the time of virological failure
was well balanced between the groups in which RT and protease
gene amplification was successful and unsuccessful, with the ex-
ception of nevirapine, which was associated with amplification
failure (P¼0.008). Amplification of both the RT and protease
genes was successful in 21%, 46%, 64%, 69%, 77%, 80% and
96% of samples from patients with plasma viral loads of 51–
100, 101–150, 151–200, 201–300, 301–500, 501–1000 and
.1000 copies/mL (P,0.001), respectively. The univariate ana-
lyses showed that age at genotyping, transmission group, CD4
count and plasma viral load at genotyping, and duration on
cART were significantly associated with unsuccessful resistance
genotyping. Multivariable analysis showed that only plasma
viral load independently predicted amplification failure: the risk
of failure was 34.6 times higher (95% CI 17.3–69.1) and 7.1
times higher (95% CI 3.0–16.7) when plasma viral load was
51–500 and 501–1000 copies/mL, respectively, than when it
was .1000 copies/mL.
Genotypic resistance patterns
The prevalence of resistance mutations to NRTIs, NNRTIs and PIs
is shown in Figure 1. The M184V and/or I mutations, selected by
lamivudine and emtricitabine, were present in 36% of patients.
NRTI resistance mutations selected by thymidine analogues
(M41L, D67N, K70R, L210W, T215Y/F and K219Q/E) were the
most frequent other mutations (10.3%–23.3%). Multiple NRTI
resistance mutations, such as the Q151M complex and the 69 in-
sertion complex, were present in 1% and 0% of samples, re-
spectively. The K65R and L74V mutations were found in 2.1%
and 6.0% of patients, respectively (Figure 1a). The most frequent
NNRTI resistance mutations were K103N and Y181C/I/V, which
were detected in 12.2% and 10.1% of patients, respectively
(Figure 1b). The prevalence of major protease resistance muta-
tions ranged from 0.3% (N83D) to 18.8% (I54L/M/V/A/T/S)
(Figure 1c). Raltegravir resistance mutations were frequent
(66%) in patients with failing raltegravir regimens (n¼35):
E92Q (n¼3), Y143R/H/C (n¼5), Q148H/R/K (n¼9) and N155H
(n¼9).
Drug resistance interpretation
The prevalence of resistance and possible resistance to drugs
belonging to the NRTI, PI and NNRTI classes ranged from 17%
(didanosine) to 37% (emtricitabine and lamivudine), from 8%
(darunavir) to 25% (indinavir) and from 11% (etravirine) to
20% (efavirenz and rilpivirine), respectively. Resistance or pos-
sible resistance to at least one antiretroviral drug was observed
in 59% of samples (at least one NRTI in 49%, one PI in 29%
and one NNRTI in 23%). The percentages of patients whose
viruses were not susceptible to any drugs in the NRTI, PI or
NNRTI classes were 8.8%, 4.5% and 8.6%, respectively.
The frequency of resistance or possible resistance to all
members of at least one drug class (NRTI, PI or NNRTI) was
16.5%. There was complete resistance to one class in 12.1% of
cases, to two classes in 3.5% of cases [NRTI+NNRTI (1.8%)
and NRTI+PI (1.1%), NNRTI+PI (0.6%)] and to all three
classes in 0.9% of cases.
Correlation between viral load and resistance
The frequency of resistance or possible resistance to at least one
antiretroviral drug increased significantly with plasma viral load:
49% in the group with plasma HIV RNA of 51–500 copies/mL,
65% in the group with plasma HIV RNA of 501–1000 copies/
mL and 67% in the group with plasma HIV RNA .1000 copies/
mL. The proportion of patients with viruses resistant to at least
one drug in the NRTI or NNRTI class was significantly higher
when plasma viral load was .500 copies/mL than when it was
51–500 copies/mL. For resistance to PIs, the proportion was
higher when the plasma viral load was .1000 copies/mL. The
percentages of patients with viral loads of 51–500, 501–1000
and .1000 copies/mL whose viruses were resistant to all NRTIs
were 6.7%, 16.5% and 13.9%, respectively (P¼0.029); the corre-
sponding proportions for PIs were 1.7%, 0% and 9.9% (P,0.001)
and those for NNRTIs were 4.3%, 10.2% and 11.5% (P¼0.029).
Comparison between 2004 and 2009
In the Multivir 2004 and 2009 studies, 498 and 259 patients, re-
spectively, had plasma HIV-RNA .1000 copies/mL, with median
plasma HIV-RNA levels of 4.0 log10 copies/mL (IQR 3.5–4.7) in
2004 and 3.9 log10 copies/mL (3.3–4.6) in 2009, of whom 85%
and 67%, respectively, had viruses with resistance or possible re-
sistance to at least one antiretroviral drug (P,0.001), as follows:
at least one NRTI in 81% and 55% of patients (P,0.001), at least
one NNRTI in 44% and 30% (P,0.001) and at least one PI in
51% and 39% (P¼0.002). The prevalence of resistance to most
drugs fell between 2004 and 2009. No difference in the preva-
lence of etravirine, saquinavir or atazanavir resistance was
found between 2009 and 2004. By contrast, resistance to daru-
navir was significantly more frequent in 2009 than in 2004. Com-
plete or possible resistance to all members of at least one drug
class was more frequent in 2004 than in 2009 (35% versus
24%, P¼0.001).
Discussion
We determined the prevalence of HIV-1 resistance to antiretro-
viral drugs in treated patients with viral loads .50 copies/mL in
2009 in France. Viral sequences were successfully obtained in
67% of 756 patients. Plasma viral load was the only factor inde-
pendently associated with the risk of amplification failure (in-
creasing from 21% for viral load 51–100 copies/mL to 96% for
.1000 copies/mL). This association is already known, but very
few studies have quantified and clearly demonstrated such a
relationship.
In 2009, 86.0% of patients included in the FHDH ANRS
CO4 were receiving cART, of whom 15.0% had viral loads
.50 copies/mL. Using the ANRS algorithm and extrapolation on
the whole French database, 8.9% of all treated patients could
contribute to the spread of resistance and 0.08% had complete
resistance to three antiretroviral drug classes.
The frequency of resistance mutations decreased significantly
over time. For example, thymidine analogue mutations (TAMs),
known to reduce viral susceptibility to most approved NRTIs,6 sig-
nificantly decreased from 16%–51% in 2004 to 10%–23% in the
2009 survey. This decline may be explained by lesser use of zi-
dovudine and stavudine, which tend to select TAMs. TAMs are
Assoumou et al.
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Figure 1. Prevalence of resistance mutations. Resistance mutations are those listed on the web site www.iasusa.org (updated autumn 2011). Major
and minor resistance mutations are indicated.
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relatively infrequent at the time of virological failure of a triple-drug
regimen. Mutation K103N, the most common mutation seen in
patients with failing regimens based on efavirenz and nevirapine,7
was present in 10.3% of cases, a proportion consistent with the
failure rate of these regimens in this study. The prevalence of
major PI mutations ranged from 0.3% (N83D) to 18.8% (I54L/M/
V/A/T/S), in keeping with the results of a previous study.8
The prevalence of resistance to at least one antiretroviral drug
was 59%, and resistance to NRTIs was more frequent than resist-
ance to PIs and NNRTIs (49%, 29% and 23%, respectively). These
prevalence rates are close to those estimated in Europe in 2008.9
The proportions of patients with viruses resistant to all drugs of
the NRTI, PI and NNRTI classes were 8.8%, 4.5% and 8.6%, re-
spectively. Regarding second-generation NNRTIs, the prevalence
of resistance ranged from 11% (etravirine) to 20% (rilpivirine).
More than 80% of viruses resistant to efavirenz or nevirapine
were also resistant to rilpivirine. This suggests that care should
be taken when using rilpivirine to treat HIV-1 infection, even in
treatment-naive patients,10 because of the high prevalence
(2.8%) of transmitted NNRTI-resistant viruses.11 Resistance to
raltegravir was only analysed in patients taking raltegravir at
the time of sampling, and was found in 66% of cases, in
keeping with data from the ANRS Aquitaine CO3 Cohort.12
We systematically investigated all treated patients with plasma
viral loads.50 copies/mL at enrolment, and found that the preva-
lence of resistance increased significantly with viral load. Interest-
ingly, the prevalence of resistance to at least one antiretroviral
drug was 49% among patients with viral loads between 51 and
500 copies/mL. This supports guidelines recommending resistance
monitoring for all patients with viral load .50 copies/mL,13–15
even if genotypic resistance tests are less efficient at low viral
loads, as shown here.
We compared the prevalence of ARV resistance observed
here with that observed in a 2004 survey, in patients with
plasma HIV-RNA .1000 copies/mL (an inclusion criterion in
the 2004 study). We found that drug resistance was less preva-
lent in 2009 than in 2004, except for darunavir. This is in
keeping with previous results.8 The decline was not statistically
significant for saquinavir and atazanavir. In contrast, the preva-
lence of resistance to darunavir was higher in 2009 than in
2004 (19% versus 12%, P¼0.008), probably because darunavir
was made available through an expanded access programme
in January 2006 in France. Thus, darunavir resistance observed
in 2004 was mainly due to cross-resistance. In 2009, in add-
ition to cross-resistance mutations, specific darunavir resistance
mutations (V11I and T74P), frequently selected during daruna-
vir failure,16 contributed to the increase in resistance observed
in 2009.
Thus, we found that, in France, resistance to antiretroviral
drugs among patients with virological failure on cART was less
frequent in 2009 than in 2004. This decline is supported by the
fact that the median plasma HIV RNA level was similar in the
two sets of samples (4.0 in 2004 versus 3.9 log10 copies/mL in
2009, P¼0.152). In addition, patients in the 2009 survey had
been exposed to much more antiretroviral treatment and for a
longer period than those in the 2004 survey.
Although this frequency may decline in future and despite the
good performance of new drugs, special attention should be paid
to patients harbouring viruses resistant to at least three ARV
classes.17
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